PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.44%
R&D growth less than half of AXSM's 5.10%. David Dodd would verify if efficiency advantage is sustainable.
34.62%
G&A growth while AXSM reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-26.41%
Other expenses reduction while AXSM shows 0.00% growth. Joel Greenblatt would examine efficiency.
14.45%
Operating expenses growth while AXSM reduces costs. John Neff would investigate differences.
14.45%
Total costs growth while AXSM reduces costs. John Neff would investigate differences.
561.32%
Interest expense growth while AXSM reduces costs. John Neff would investigate differences.
-26.41%
D&A reduction while AXSM shows 100.24% growth. Joel Greenblatt would examine efficiency.
55.40%
EBITDA growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-14.45%
Operating income decline while AXSM shows 0.78% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
231.19%
Other expenses growth while AXSM reduces costs. John Neff would investigate differences.
43.33%
Pre-tax income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
561.32%
Tax expense growth above 1.5x AXSM's 138.53%. Michael Burry would check for concerning trends.
43.33%
Net income growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
43.35%
EPS growth while AXSM declines. John Neff would investigate advantages.
43.35%
Diluted EPS growth while AXSM declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.